SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-311031
Filing Date
2022-12-22
Accepted
2022-12-22 16:09:02
Documents
12
Period of Report
2022-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d351807d8k.htm   iXBRL 8-K 20712
  Complete submission text file 0001193125-22-311031.txt   138136

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA itci-20221219.xsd EX-101.SCH 2897
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20221219_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20221219_pre.xml EX-101.PRE 10844
6 EXTRACTED XBRL INSTANCE DOCUMENT d351807d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 221482057
SIC: 2834 Pharmaceutical Preparations